Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

95 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Mechanisms of MYC stabilization in human malignancies.
Junttila MR, Westermarck J. Junttila MR, et al. Among authors: westermarck j. Cell Cycle. 2008 Mar 1;7(5):592-6. doi: 10.4161/cc.7.5.5492. Epub 2007 Dec 29. Cell Cycle. 2008. PMID: 18256542 Review.
Arpp19 Promotes Myc and Cip2a Expression and Associates with Patient Relapse in Acute Myeloid Leukemia.
Mäkelä E, Löyttyniemi E, Salmenniemi U, Kauko O, Varila T, Kairisto V, Itälä-Remes M, Westermarck J. Mäkelä E, et al. Among authors: westermarck j. Cancers (Basel). 2019 Nov 11;11(11):1774. doi: 10.3390/cancers11111774. Cancers (Basel). 2019. PMID: 31717978 Free PMC article.
(2S, 4R)-4-[18F]Fluoroglutamine for In vivo PET Imaging of Glioma Xenografts in Mice: an Evaluation of Multiple Pharmacokinetic Models.
Miner MW, Liljenbäck H, Virta J, Merisaari J, Oikonen V, Westermarck J, Li XG, Roivainen A. Miner MW, et al. Among authors: westermarck j. Mol Imaging Biol. 2020 Aug;22(4):969-978. doi: 10.1007/s11307-020-01472-1. Mol Imaging Biol. 2020. PMID: 31993927 Free PMC article.
Phosphoproteome and drug-response effects mediated by the three protein phosphatase 2A inhibitor proteins CIP2A, SET, and PME-1.
Kauko O, Imanishi SY, Kulesskiy E, Yetukuri L, Laajala TD, Sharma M, Pavic K, Aakula A, Rupp C, Jumppanen M, Haapaniemi P, Ruan L, Yadav B, Suni V, Varila T, Corthals GL, Reimand J, Wennerberg K, Aittokallio T, Westermarck J. Kauko O, et al. Among authors: westermarck j. J Biol Chem. 2020 Mar 27;295(13):4194-4211. doi: 10.1074/jbc.RA119.011265. Epub 2020 Feb 18. J Biol Chem. 2020. PMID: 32071079
CIP2A inhibits PP2A in human malignancies.
Junttila MR, Puustinen P, Niemelä M, Ahola R, Arnold H, Böttzauw T, Ala-aho R, Nielsen C, Ivaska J, Taya Y, Lu SL, Lin S, Chan EK, Wang XJ, Grènman R, Kast J, Kallunki T, Sears R, Kähäri VM, Westermarck J. Junttila MR, et al. Among authors: westermarck j. Cell. 2007 Jul 13;130(1):51-62. doi: 10.1016/j.cell.2007.04.044. Cell. 2007. PMID: 17632056
MYC-dependent regulation and prognostic role of CIP2A in gastric cancer.
Khanna A, Böckelman C, Hemmes A, Junttila MR, Wiksten JP, Lundin M, Junnila S, Murphy DJ, Evan GI, Haglund C, Westermarck J, Ristimäki A. Khanna A, et al. Among authors: westermarck j. J Natl Cancer Inst. 2009 Jun 3;101(11):793-805. doi: 10.1093/jnci/djp103. Epub 2009 May 26. J Natl Cancer Inst. 2009. PMID: 19470954
CIP2A increases self-renewal and is linked to Myc in neural progenitor cells.
Kerosuo L, Fox H, Perälä N, Ahlqvist K, Suomalainen A, Westermarck J, Sariola H, Wartiovaara K. Kerosuo L, et al. Among authors: westermarck j. Differentiation. 2010 Jul;80(1):68-77. doi: 10.1016/j.diff.2010.04.003. Epub 2010 May 5. Differentiation. 2010. PMID: 20447748
Identification of a c-Jun N-terminal kinase-2-dependent signal amplification cascade that regulates c-Myc levels in ras transformation.
Mathiasen DP, Egebjerg C, Andersen SH, Rafn B, Puustinen P, Khanna A, Daugaard M, Valo E, Tuomela S, Bøttzauw T, Nielsen CF, Willumsen BM, Hautaniemi S, Lahesmaa R, Westermarck J, Jäättelä M, Kallunki T. Mathiasen DP, et al. Among authors: westermarck j. Oncogene. 2012 Jan 19;31(3):390-401. doi: 10.1038/onc.2011.230. Epub 2011 Jun 27. Oncogene. 2012. PMID: 21706057
CIP2A signature reveals the MYC dependency of CIP2A-regulated phenotypes and its clinical association with breast cancer subtypes.
Niemelä M, Kauko O, Sihto H, Mpindi JP, Nicorici D, Pernilä P, Kallioniemi OP, Joensuu H, Hautaniemi S, Westermarck J. Niemelä M, et al. Among authors: westermarck j. Oncogene. 2012 Sep 27;31(39):4266-78. doi: 10.1038/onc.2011.599. Epub 2012 Jan 16. Oncogene. 2012. PMID: 22249265
95 results
Jump to page